Brief: Innate Pharma Presents Data From Ongoing Phase 2 Tellomak Trial

Innate Pharma SA

23/09/2022 06:04

Sept 23 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA PRESENTS DATA FROM ONGOING PHASE 2 TELLOMAK
TRIAL
DEMONSTRATING CLINICAL ACTIVITY OF LACUTAMAB IN ADVANCED MYCOSIS
FUNGOIDES
    * PRELIMINARY DATA SET PRESENTED AT EORTC CLTG ANNUAL
MEETING
CONFIRMS CLINICAL ACTIVITY AND FAVORABLE SAFETY PROFILE OF
LACUTAMAB IN PATIENTS WITH MYCOSIS FUNGOIDES WHO EXPRESS KIR3DL2
AND WHO WERE PREVIOUSLY TREATED WITH AT LEAST TWO LINES OF
SYSTEMIC THERAPY
    * RESULTS SHOWED THAT LACUTAMAB PRODUCED A GLOBAL OBJECTIVE
RESPONSE RATE (ORR) OF 28.6% (95% CONFIDENCE INTERVAL  CI ,
13.8-50.0) IN THE KIR3DL2-EXPRESSING MF PATIENTS (N=21),
INCLUDING 2 COMPLETE RESPONSES AND 4 PARTIAL RESPONSES

Source text for Eikon:  ID:nBw6JxxV5a 
Further company coverage:  IPH.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))